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Abstract:  Gamma-hydroxybutyric  acid  (GHB)  is  a  short-chain  fatty  acid  structurally 
similar  to  the  inhibitory  neurotransmitter  -aminobutyric  acid.  Clinical  trials  have 
demonstrated that 50-100 mg/kg of GHB fractioned into three or six daily doses is able to 
suppress alcohol withdrawal symptoms and facilitates the maintenance of abstinence from 
alcohol.  These  studies  have  also  shown  that  GHB  craving  episodes  are  a  very  limited 
phenomenon  (about  10-15%).  Thus,  physicians  with  access  should  consider  the  clinical 
efficacy of GHB as a valid pharmacological tool for the treatment of alcohol addiction. 
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1. Introduction 
 
Gamma hydroxybutyric acid (GHB) was synthesized in 1960 in an attempt to create an analogue of 
the ubiquitous inhibitory brain neurotransmitter gamma-aminobutyric acid (GABA) that would cross 
the blood-brain barrier [1-3]. GHB was first developed as a central nervous system depressant [4,5] 
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and used as an anesthetic adjuvant for minor surgical procedures in laboratory as well as in clinical 
settings [6-11]. The use of GHB as an anesthetic is now decreasing, even though it is still approved in 
Germany for intravenous anesthesia [1]. In the 1970s, GHB was found to be effective in the treatment 
of narcolepsy [12-15]. In particular, nightly doses of GHB were shown to improve the structure of 
sleep in narcoleptic patients, reducing the number of nocturnal awakenings and daytime attacks of 
cataplexy [16-18]. In the United States, through a limited distribution program, the FDA approved 
GHB as a Schedule III Controlled Substance to treat a small subset of patients with narcolepsy who 
have episodes of weak or paralyzed muscles (i.e. cataplexy) [19]. In addition, since 1992, GHB has 
been approved in Italy and Austria as a treatment for alcohol dependence [20]. 
 
2. Metabolism 
 
GHB occurs naturally in mammalian brain tissue [21]. The primary precursor of GHB in the brain 
is GABA, which is transformed into succinic semialdehyde (SSA) through a GABA-transaminase and 
then  converted  into  GHB  via  a  specific  succinic  semialdehyde  reductase  (SSR).  GHB  can  be 
reconverted  to  SSA  via  a  GHB  dehydrogenase,  and  then  SSA  can  be  converted  back  to  GABA  
(Figure  1);  SSA  can  also  be  transformed  by  succinic  semialdehyde  dehydrogenase  (SSADH)  into 
succinic acid and then further metabolized via the Krebs Cycle in mitochondria (Figure 1). GHB is 
primarily eliminated by the liver, and only a modest quantity of it remains unmodified (2-5%) and 
eliminated with urine and/or by a still not fully ascertained process of beta-oxidation (Figure 1) [21]. 
 
Figure 1. GHB metabolism in the central nervous system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GHBDH:  GHB  dehydrogenase;  SSR:  succinic  semialdehyde  reductase;  SSA:  succinic 
semialdehyde;  GABA:  gamma-aminobutyric  acid;  GABAT:  GABA-transaminase;  SSADH: 
succinic semialdehyde dehydrogenase. 
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Exogenous GHB is rapidly absorbed by the gastro-intestinal tract; its peak plasma concentration 
appears  after  15-45  minutes,  and  its  clinical  effects  after  15-20  minutes.  This  drug  has  a  dose-
dependent elimination half-life; in healthy subjects this can vary from 20 to 53 minutes [22]. 
 
3. Neuro-Modulatory Properties 
 
In  the  central  nervous  system,  GHB  binds  to  GHB  and  GABAB  receptors  with  high  and  low 
affinity, respectively [21]. The endogenous neurobiological activity of GHB is mediated through the 
GHB receptor, while many of the pharmacological and clinical effects of exogenously administered 
GHB appear to be mediated through the GABAB receptor, where GHB may act both directly, as a 
partial GABAB receptor agonist, and indirectly through GHB-derived GABA [1,21]. Irrespective of 
the  brain  GHB  concentration,  it  is  far  from  certain  that  GHB  interacts  directly  with  the  GABAA 
receptors [1,21,22]. However, the conversion of exogenously administered GHB to GABA induces an 
activation of GABAB receptor and GABAA receptors too [1,21,22] and this is responsible of GHB 
sedative and anxiolitic effects. 
Physiologically,  the  mesocorticolimbic  dopaminergic  neurons  (DA)  are  involved  in  reward-
dependent learning (Figure 2a). DA have their cell bodies in the ventral tegmental area (VTA) and 
project  into  the  basal  forebrain  structures,  such  as  the  nucleus  accumbens  (NAc),  amygdala,  and 
frontal and limbic cortexes [21]. Activation of DA, with a resultant increase in the output of dopamine 
in innervated projection structures, has been reported with virtually all major drugs of abuse. It is 
supposed that the alcohol-mimetic effect of GHB appears to be related to the effects of the dopamine 
increase mediated by GABAB receptors in mesocorticolimbic circuitry [21]. 
 
Figure 2. Activity of meso-corticolimbic system in physiological condition (a), and during 
exogenous administration of GHB (b). 
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Figure 2. Cont. 
 
“-“: inhibition; “+” : activation;  : dopamine 
(a) dopaminergic  neurons (DA) originate from  ventral tegmental area (VTA) and project their 
fibres to the nucleus accumbens (NAc) and to the pre-frontal cortex; DA neurons play a relevant 
role in physiological reward (i.e. food, sleeping, sexual activity); this circuit is often inhibited by 
noradrenergic and GABA-ergic neurons originated from the locus ceruleus (LC). 
(b) GHB induces dis-inhibition of DA originated from  VTA through DA direct activation and 
inhibition  of  GABA-ergic  and  noradrenergic  neurons  with  a  consequent  increase  in  dopamine 
release from NAc and pre-frontal cortex; this mechanism is on the basis of the alcohol-mimicking 
effect of GHB. 
 
Both endogenous and exogenous forms of GHB have a dual action on the GHB receptors and the 
GABAB receptors. GHB that binds with high affinity to the pre-synaptic GHB receptors decreases the 
release of GABA, while GHB that binds with a low-affinity site on the GABAB receptors increases 
activation of cell-surface receptors. Therefore, the administration of exogenous GHB is primarily able 
to decrease the release of GABA from the pre-synaptic GABA-ergic neurons through effects mediated 
by a direct activation of GHB receptors [21]. The result would be disinhibition of DA of the VTA with 
increased dopamine within that circuitry, and this is responsible of the alcohol mimic effect of GHB 
(Figure 2b) [21]. Finally, GHB has been recently shown to decrease the activity of neurons in the locus 
ceruleus (LC), providing  yet another route by which GHB could disinhibit  mesocorticolimbic DA 
(Figure 2b) [21]. 
In summary, data indicate that sedative effect of exogenously administered GHB (high dose) may 
be due to a direct effect on GABAB and  indirect on GABAA receptors: mainly 100  mg/kg/day to 
suppress alcohol withdrawal syndrome (AWS) and from 4 to 9 g/day to treat cataplexy in narcoleptic 
patients. On the other hand, the alcohol-mimic mechanism of exogenously administered GHB (low 
dose) may be due to a decrease in the release of GABA through the effects mediated by GHB receptors 
on  pre-synaptic  GABA-ergic  and  noradrenergic  neurons,  with  a  resultant  disinhibition  of  DA  and 
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increase  in  dopaminergic  activity  in  the  mesocorticolimbic  circuitry  (Figure  2b)  [21]:  mainly  
50 mg/kg/day to suppress craving for alcohol intake. 
 
4. GHB for the Treatment of Alcohol Withdrawal Syndrome 
 
AWS  is  mediated  by  a  reduced  GABA-ergic  activity  in  the  central  nervous  system  [25-27]. 
Exogenous GHB suppresses AWS symptoms in humans by an indirect activation of GABAA receptors 
due to the conversion of GHB to GABA [21]. Such a GABA-ergic activity triggers chloride transport 
across the neuronal membrane, thus inducing a decreased neuronal excitability [28] with consequent 
resolution of AWS symptoms. 
In the clinical area, the efficacy of a non-benzodiazepine GABA-ergic compound such as GHB in 
suppressing  AWS  is  well  demonstrated  [29].  After  the  first  pilot  study  [30],  a  single-blind  trial 
comparing  GHB  versus  diazepam  did  not  show  a  significant  different  efficacy  of  these  drugs  in 
suppressing  AWS [31], even though GHB reduced anxiety, agitation and current depression  more 
rapidly than diazepam [31]. A more recent study, however, demonstrated that GHB was even more 
effective than diazepam in treating AWS [32]. GHB has also been found to be equally efficient as 
clomethiazole [33], and its efficacy was further confirmed by treating AWS in almost three hundred 
hospitalized patients affected by different conditions, such as for medical, neurological or psychiatric 
diseases, trauma or surgery [34]. In all these studies, GHB was employed at the dose of 50-100 mg/kg 
divided into three or four daily administrations, and no serious side effects were reported. 
 
5. GHB as an Anti-Craving Drug in the Maintenance of Alcohol Abstinence 
 
5.1. Studies with GHB as Mono-Therapy 
 
As  mentioned  above,  GHB  exerts  an  ethanol-mimicking  effect  on  the  central  nervous  
system  [35-37].  Consistent  with  this  rationale,  GHB  has  been  shown  to  be  capable  of  inhibiting 
voluntary ethanol consumption  in rats that have a preference for ethanol  [35,37,38]. In humans, a 
randomized double-blind study treating patients with GHB at dose of 50 mg/kg (divided into three 
daily administrations) or placebo for three months showed that GHB  was significantly  superior to 
placebo in increasing the number of abstinent days, in reducing the number of daily drinks and in 
reducing alcohol craving [39]. Another open multi-centre study confirmed the efficacy of GHB in 
improving  the  abstinence  rate  and  in  reducing  craving  for  alcohol  [40].  GHB  also  proved  to  be 
manageable,  with  few  side-effects,  such  as  dizziness,  sleepiness  and  tiredness  early  on  during 
treatment (usually resolved after 2-3 weeks). Despite these results, about 30-40% of alcoholics treated 
with GHB fail to achieve complete abstinence from alcohol even though they sometimes describe a 
temporary reduction of alcohol craving. Taking into account the short half-life of GHB [22,23], a study 
was, then, conducted to investigate the efficacy of the administration of a greater fractioning (six times 
a  day)  of  the  same  dose  (50  mg/kg)  of  GHB  in  those  subjects  who  have  not  achieved  alcohol 
abstinence  after  the  administration  of  three  daily  doses  of  this  drug  [41].  The  results  showed  a 
significant reduction of alcohol craving in a greater percentage of alcoholics who were able to achieve 
complete abstinence from alcohol. Int. J. Environ. Res. Public Health 2009, 6                 
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More recently, a one-year open-label study tested the efficacy of GHB (doses ranging between  
25  and  100  mg/kg/day)  in  “treatment-resistant”  chronic  alcoholics  defined  as  patients  who  have 
previously followed at least two attempts at treatment [i.e. use of psychoactive drugs such as selective 
serotonin reuptake inhibitors, mood stabilizers, tricycles and/or self-help group intervention] without 
achieving alcohol abstinence or those who relapsed into heavy drinking during attendance at self-help 
groups or who were not helped in achieving alcohol abstinence by their precarious psycho-social or 
environmental  conditions  [42].  The  results  of  the  study  showed  that  60%  of  patients  were 
“responders”, i.e., patients who successfully achieved complete abstinence from alcohol together with 
social adjustment (full-responders) or patients who reduced their alcohol intake but did not accomplish 
complete alcohol abstinence (partial-responders) [42]. The retention rate during treatment with GHB 
was, therefore, significantly higher than the retention rate of the same sample treated with previous 
pharmaco-therapies.  Furthermore,  this  study  confirmed  that  the  only  significant  predictor  of  the 
retention  rate  was  the  six-times/daily  fractionated  administration  of  GHB  [42],  a  result  in  close 
agreement with the previous study [41]. 
Laboratory studies with healthy subjects investigating the effects of administering alcohol and a 
single dose of GHB 50 mg/kg together showed an increased rate of side-effects, probably due to the 
combination  of  GHB  and  alcohol  [43].  This  effect  was  not  observed  in  the  clinical  studies  with 
alcoholics reported above. In fact, no side effects due to the combination of GHB 50 mg/kg (divided 
into 3 to 6 daily administration) and alcohol were observed in those GHB-treated alcoholics who were 
still drinking during the treatment [39-41,44,45]. It is conceivable that the use of the same dose of  
50 mg/kg divided into 3-6 daily administrations was able to prevent the occurrence of unsafe effects 
when associated with ethanol [46]. 
 
5.2. Comparative Studies 
 
A  3-month  open  randomized  comparative  study  evaluating  the  efficacy  of  oral  doses  of  GHB  
(50  mg/kg  of  body  weight  t.i.d)  compared  with  oral  doses  of  naltrexone  (NTX)  (50  mg/day)  in 
maintaining abstinence from alcohol in patients mostly with moderate dependence showed a better 
efficacy with GHB than NTX (66.7% vs 35.3%, P < 0.02) [44]. Nevertheless, in the same study, in the 
NTX group patients who failed to be abstinent did not relapse into heavy drinking, confirming the 
ability of this drug to reduce alcohol relapses, while in the GHB group all the patients who did not 
maintain abstinence relapsed into heavy drinking (11%). Craving for GHB was not observed, and no 
sedative additive effects due to alcohol and GHB interaction in patients who relapsed, drug withdrawal 
syndrome or side effects due to drug suspension on drug discontinuation were shown. Moreover, a  
12-month comparative study showed that, despite a trend in favor of GHB, this drug administered at a 
dose of 50 mg/kg/day, NTX at a dose of 50 mg/day, and disulfiram at a dose of 200 mg/day proved to 
have a similar effect in maintaining alcohol abstinence at the end of treatment, 65%, 49% and 40%, 
respectively [47]. None of the patients belonging to the GHB group developed craving for this drug, 
and side-effects were well tolerated in all groups. 
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5.3. Combined Studies 
 
Considering the data emerging from the comparative studies, one hypothesis arose: are GHB and 
NTX able to work better if combined together, taking advantage of the former’s alcohol-mimicking 
effect and the latter’s anti-reward property? In order to confirm this suggestion, a 3-month randomized 
study was performed in patients mostly with severe alcohol dependence [45]. In this 3-month open 
randomized comparative study, the combined treatment of GHB and NTX  was shown to be  more 
effective in maintaining abstinence from alcohol than GHB and NTX used singly, 72.2%, 40% and 
5.9%,  respectively  [45].  The  number  of  relapses  into  heavy  drinking  also  tended  to  occur  less 
frequently in the combination group (no cases) than in either the GHB group or the NTX group. These 
data support the above-mentioned preliminary hypothesis suggesting that the two drugs may combine 
their  different  actions  synergistically  without  suppressing  the  favorable  effects  of  each  other.  In 
addition, as demonstrated by the absence of patients who developed craving for GHB in the combined 
group  with  respect  to  the  group  taking  GHB  alone  (10%)  [45],  it  may  be  hypothesized  that  a 
modulation effect induced by the anti-reward property of NTX is able to avoid the onset of craving for 
GHB  as  previously  also  demonstrated  by  three  clinical  experiences  [48].  Another  6-month  open 
randomized study evaluating whether GHB or NTX or its combination could help to maintain alcohol 
abstinence in patients following a treatment with escitalopram, an anti-depressant agent belonging to 
the category of selective serotonin reuptake inhibitors, has also been performed [49]. In this study the 
combination therapy in association with escitalopram proved to be more efficient in preventing alcohol 
relapses than GHB plus escitalopram, NTX plus escitalopram or escitalopram given alone, 83.3%, 
50%,  33.3%,  and  18.1%,  respectively  [49].  In  fact,  the  craving  mechanism  implicated  in  alcohol 
addiction  may  differ  in  different  subtypes  of  alcohol-dependent  patients  [50,51].  In  particular, 
dopaminergic/opioidergic  deregulation  has  been  implicated  in  reward  craving,  GABA 
ergic/glutamatergic  deregulation  in  relief  craving,  and  serotonergic  deregulation  in  obsessive  
craving [50-52]. It is possible that different craving conditions and profiles co-exist in a single patient, 
which is why drug combinations (association of GHB, NTX and escitalopram) could be more effective 
than mono-therapy in reducing relapses. An understanding of the different forms of craving could have 
important implications particularly in the field of anti-craving drug therapy. 
 
6. Craving for and Abuse of GHB in Clinical Studies 
 
Craving  for  and  abuse  of  GHB  remains  one  of  the  crucial  points  during  the  use  of  this  drug. 
However, episodes of craving for GHB in alcoholics, when manifested, are a very limited phenomenon 
(about 10%) [53]; on the other hand, it is to be hoped that better manageability and safety of GHB can 
probably be improved with the identification of groups of alcoholics more predisposed to develop this 
unfavorable effect. A study investigating the risk of developing craving for and abuse of GHB among 
different types of alcoholics was, therefore, performed [54]. In this study, indeed, 47 patients were 
enrolled and divided into four different sub-types of alcoholics, and treated with an oral dose of GHB 
(50 mg/kg of body weight fractioned into three daily administrations) for three months. At the end of 
the study, besides a general efficacy of GHB in maintaining alcohol abstinence in all four groups of 
patients,  craving  for  GHB  was  statistically  significantly  higher  in  those  alcoholics  with  previous Int. J. Environ. Res. Public Health 2009, 6                 
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cocaine dependence than in “pure” alcoholics (patients with a diagnosis of alcohol dependence without 
other addictive disorders) (90% vs 14.3%, P < 0.001), with 60% abuse of it [54]; however, craving for 
GHB did not differ between “pure” alcoholics and alcoholics with previous heroin dependence except 
for the fact that all alcoholics with previous heroin dependence abused GHB, while none of the “pure” 
alcoholics  manifested  this  addiction.  The  greater  incidence  of  craving  for  and  abuse  of  GHB  in 
alcoholics with a previous diagnosis of cocaine or heroin dependence is an interesting finding and may 
be putatively explained by the alteration of dopamine system [55]. It has been clearly described that 
patients with previous chronic exposure to heroin or cocaine may present a down-regulation of D1 and 
D2  receptors,  and  only  high  doses  of  GHB  (>  50  mg/kg/die)  may  exert  a  reward  effect  [56,57]. 
Moreover, imaging studies with positron emission tomography have shown that chronic exposure to 
cocaine, alcohol or opiates down regulates D2 receptors in striatum, and these adaptations may persist 
for  a  long  time  after  substance  cessation  [58].  In  addition,  chronic  exposure  to  cocaine  reduces 
GABAB receptor activity in the meso-cortico-limbic area [59,60]. The consequence is a reduction in 
dopamine release, which persists after cocaine cessation. As GHB acts on GABAB receptors, it is 
likely that alcoholics with previous cocaine addiction present a down-regulated GABAB system and 
are  more  predisposed  to  develop  craving  and  episodes  of  abuse  of  GHB.  Thus,  GHB,  a  GABAB 
receptor agonist, may act as a substitutive drug, so that alcoholics with previous cocaine or heroin 
addiction tend to become predisposed to misuse of the drug. Interestingly, in the above mentioned 
study [54], alcoholics following a methadone maintenance treatment (MMT) program did not develop 
craving  for GHB. As some recent studies have shown that MMT may  induce a μ-opioid receptor 
desensitization  in  rats  [61]  and  a  long-lasting  striatum  dopamine  neuron  impairment  in  heroin  
users [62], a dopamine independent pathway may be responsible for these results; the low percentage 
of  subjects  who  failed  to  maintain  abstinence  for  alcohol  in  the  MMT  group  may  confirm  this 
hypothesis. 
 
7. Conclusions 
 
Available studies have demonstrated that GHB appears to be effective both in the management of 
AWS and in the maintenance of long-term abstinence from alcohol [63,64]. Moreover, it is worth 
noting  that  all  the  cited  clinical  trials  have  clearly  demonstrated  that  GHB  discontinuation  is  not 
followed by withdrawal syndrome, irrespective of its use for treating AWS or maintaining abstinence 
from alcohol; therefore, the discontinuation of GHB does not require a tapering procedure [65]. None 
of the above-mentioned trials reported serious side effects during the treatment of GHB; in addition, 
the fractioning of the GHB doses, from three to six daily administrations, avoided the occurrence of 
additive  sedative  effects  in  patients  who  voluntarily  use  alcohol  during  the  treatment  with  this  
drug [44-46]. Moreover, due to its short half-life (4-6 hours) [23], GHB may be also safe in patients 
with decompensated liver disease with ascites effusion [24]; however, this data needs to be confirmed 
by further clinical trials.  Furthermore, even though rare and transitory episodes of sedation due to 
GHB abuse have been reported, no cases of intoxication, coma or deaths have occurred when the drug 
is  administered  under  a  medical  supervision  [40,54].  On the other  hand,  when  GHB  is  used  as  a 
recreational drug of abuse (non-clinical use), several cases of intoxication and even death after a single 
and self-administered dose of the “street” formulation have been reported [66-68]. Int. J. Environ. Res. Public Health 2009, 6                 
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In  conclusion,  we  believe  that  specialists  in  the  treatment  of  alcohol  addiction  should  be  less 
concerned by the risk of GHB intoxication when this drug is employed for treating alcoholism under 
close  medical  surveillance.  They  should  not  be  discouraged  from  using  GHB  in  the  treatment  of 
alcohol  addiction,  as  long  as  some  rules  are  followed  during  its  administration:  a)  not  exceeding  
50-100 mg/kg fractioned into three to six daily administrations; b) using GHB only for the treatment of 
pure  alcoholics,  and  avoiding  this  drug  for  those  alcoholics  with  previous  cocaine  or  heroin 
dependence; c) planning strict medical surveillance (weekly visits) and designating a family member 
to whom GHB should be entrusted [69]. The safety and efficacy of GHB, thus, need to be emphasized, 
as this drug represents a most useful tool for treating alcohol dependence [70,71]. 
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